Search

Displaying results 571 - 580 of 4591 in total
  1. Drug

    Finafloxacin

    go.drugbank.com/drugs/DB09047
    ApprovedWithdrawn

    Finafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014. … Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.

  2. Drug

    Itraconazole

    go.drugbank.com/drugs/DB01167
    ApprovedInvestigational

    [L50051] Itraconazole was first approved in the US in 1992 [L50056] and is available orally. … While the intravenous formulation of the drug was formerly available, it was discontinued in the US in 2007.[A263232]

  3. Drug

    gamma-Hydroxybutyric acid

    go.drugbank.com/drugs/DB01440
    ApprovedIllicitInvestigational

    It is currently regulated in the US and sold by Jazz Pharmaceuticals under the name Xyrem. However, it is important to note that GHB is a designated Orphan drug (in 1985).

  4. Drug

    Leniolisib

    go.drugbank.com/drugs/DB16217
    ApprovedInvestigational

    [L45758] APDS is a primary immunodeficiency caused by mutations in genes encoding the PI3Kδ, thereby increasing the activity of PI3Kδ, causing immune dysfunction, and elevating susceptibility to infections

  5. Drug

    Axicabtagene ciloleucel

    go.drugbank.com/drugs/DB13915
    ApprovedInvestigational

    [A216163] Axicabtagene ciloleucel was approved by the FDA on October 18th, 2017. … [L40054] Axicabtagene ciloleucel was later approved by the EMA on August 23, 2018.[L42090]

  6. Drug

    Zoliflodacin

    go.drugbank.com/drugs/DB12817
    ApprovedInvestigational

    Gonorrhea, caused by Neisseria gonorrhoeae, presents a significant public health challenge due to increasing antimicrobial resistance. … [A275268] Zoliflodacin is a first-in-class spiropyrimidinetrione antibiotic designed to address this need by inhibiting bacterial type II topoisomerases (DNA gyrase and topoisomerase IV), thereby blocking

  7. Drug

    Cerliponase alfa

    go.drugbank.com/drugs/DB13173
    ApprovedInvestigational

    [L51339] It was also approved by the EMA on May 30, 2017 [L51324] and by Health Canada on December 19, 2018. … [L51319] On April 27, 2017, cerliponase alfa was first approved by the FDA as the first treatment for neuronal ceroid lipofuscinosis type 2 (CLN2), also known as TPP1 deficiency.

  8. Drug

    Lutetium Lu-177 vipivotide tetraxetan

    go.drugbank.com/drugs/DB16778
    ApprovedInvestigational

    [L43787] In December 2022, lutetium Lu-177 vipivotide tetraxetan was approved by the EMA.[L43787,L45533] … [L41280] Lutetium Lu-177 vipivotide tetraxetan was first approved by the FDA on March 23, 2022 as a treatment for prostate-specific membrane antigen–positive metastatic castration-resistant prostate

  9. Drug

    Ipecac

    go.drugbank.com/drugs/DB13293
    ApprovedWithdrawn

    [L2753] Ipecac was approved by Health Canada as an OTC but all those products are now discontinued.

  10. Drug

    Amphetamine

    go.drugbank.com/drugs/DB00182
    ApprovedIllicitInvestigational

    This use derived into a large overproduction of amphetamine and all the surplus after the war finalized ended up in the black market, producing the initiation of the illicit abuse.[A18540] … Amphetamine, with the chemical formula alpha-methylphenethylamine, was discovered in 1910 and first synthesized by 1927.